Robust Linear Longitudinal Feedback Control of a Flapping Wing Micro Air Vehicle

This paper falls under the idea of introducing biomimetic miniature air vehicles in ambient assisted living and home health applications. The concepts of active disturbance rejection control and flatness based control are used in this paper for the trajectory tracking tasks in the flapping-wing miniature air vehicle (FWMAV) time-averaged model. The generalized proportional integral (GPI) observers are used to obtain accurate estimations of the flat output associated phase variables and of the time-varying disturbance signals. This information is used in the proposed feedback controller in (a) approximate, yet close, cancelations, as lumped unstructured time-varying terms, of the influence of the highly coupled nonlinearities and (b) the devising of proper linear output feedback control laws based on the approximate estimates of the string of phase variables associated with the flat outputs simultaneously provided by the disturbance observers. Numerical simulations are provided to illustrate the effectiveness of the proposed approach

Wireless sensing and identification of passive electromagnetic sensors based on millimetre-wave

Abstract — The wireless measurement of various physical quantities from the analysis of the RADAR Cross Sections variability of passive electromagnetic sensors is presented. A millimetre-wave Frequency-Modulated Continuous-Wave RADAR is used for both remote sensing and wireless identification of sensors. Long reading ranges (up to some decameters) may be reached at the expense of poor measurement resolution (typically 10%). T I

Wireless Sensing and Identification based on RADAR Cross Sections Variability Measurement of Passive Electromagnetic Sensors

International audienceIn this paper we present the wireless measurement of various physical quantities from the analysis of the RADAR Cross Sections (RCS) variability of passive electromagnetic sensors. The technique uses a millimeter Frequency-Modulated Continuous-Wave (FMCW) RADAR for both remote sensing and wireless identification of sensors. Long reading ranges (up to some decameters) is reached at the expense of poor measurement resolution (typically 10%). A review of recent experimental results is reported for illustration purpose

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

BACKGROUND: A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. METHODS: In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P=0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard-therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P=0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P=0.003). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number, NCT00439777.)